Literature DB >> 23180890

Design and synthesis of boron containing potential pan-RAR inverse agonists.

Bhaskar C Das1, Xiang-Ying Tang, Todd Evans.   

Abstract

We designed and successfully synthesized the compounds 5 and 8 as potential pan-RAR (retinoic acid receptor) agonists. These two compounds were designed based on an existing pan-RAR agonist (BMS493). We synthesized compound 5, in which the carboxylic acid group in BMS 493 was replaced by boronic ester; and compound 8, in which the double bond of BMS 493 was changed to an oxadiazole (as bioisosteres of double bond) ring. The two target molecules 5 and 8 were synthesized from the commercially available 7-bromo-4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one 1. Compound 1 was derivatized to intermediate 5,5-dimethyl-8-(phenylethynyl)-5,6-dihydronaphthalene-2 carbaldehyde 4 by using alkylation, dehydration, and metal exchange reactions. The intermediate 4 was further converted to 5 by using a Wittig reaction and to 8 by amide coupling and dehydration to give overall 18% and 33% yields, respectively, after 8 steps in each case.

Entities:  

Year:  2012        PMID: 23180890      PMCID: PMC3505081          DOI: 10.1016/j.tetlet.2011.12.118

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  21 in total

Review 1.  The liver X receptor gene team: potential new players in atherosclerosis.

Authors:  Joyce J Repa; David J Mangelsdorf
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

Review 2.  Retinoid x receptor heterodimers in the metabolic syndrome.

Authors:  Andrew I Shulman; David J Mangelsdorf
Journal:  N Engl J Med       Date:  2005-08-11       Impact factor: 91.245

Review 3.  The promise of retinoids to fight against cancer.

Authors:  L Altucci; H Gronemeyer
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 4.  Nuclear receptors and lipid physiology: opening the X-files.

Authors:  A Chawla; J J Repa; R M Evans; D J Mangelsdorf
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

5.  Potentially Macrocyclic Peptidyl Boronic Acids as Chymotrypsin Inhibitors.

Authors:  Zong-Qiang Tian; Bradley B. Brown; David P. Mack; Craig A. Hutton; Paul A. Bartlett
Journal:  J Org Chem       Date:  1997-02-07       Impact factor: 4.354

6.  A forward chemical screen in zebrafish identifies a retinoic acid derivative with receptor specificity.

Authors:  Bhaskar C Das; Kellie McCartin; Ting-Chun Liu; Randall T Peterson; Todd Evans
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

7.  Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists.

Authors:  Pierre Germain; Claudine Gaudon; Vivian Pogenberg; Sarah Sanglier; Alain Van Dorsselaer; Catherine A Royer; Mitchell A Lazar; William Bourguet; Hinrich Gronemeyer
Journal:  Chem Biol       Date:  2009-05-29

8.  Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.

Authors:  Bhaskar C Das; Melissa E Smith; Ganjam V Kalpana
Journal:  Bioorg Med Chem Lett       Date:  2008-05-29       Impact factor: 2.823

Review 9.  International Union of Pharmacology. LX. Retinoic acid receptors.

Authors:  Pierre Germain; Pierre Chambon; Gregor Eichele; Ronald M Evans; Mitchell A Lazar; Mark Leid; Angel R De Lera; Reuben Lotan; David J Mangelsdorf; Hinrich Gronemeyer
Journal:  Pharmacol Rev       Date:  2006-12       Impact factor: 25.468

10.  In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.

Authors:  Melissa E Smith; Bhaskar C Das; Ganjam V Kalpana
Journal:  Cancer Cell Int       Date:  2011-09-27       Impact factor: 5.722

View more
  1 in total

Review 1.  Boron chemicals in diagnosis and therapeutics.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Caroline Schinke; Sasmita Das; Suman Kambhampati; Sushanta K Banerjee; Peter Van Veldhuizen; Amit Verma; Louis M Weiss; Todd Evans
Journal:  Future Med Chem       Date:  2013-04       Impact factor: 3.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.